newsfilter
← Latest News
Business Wire·

Acorda Therapeutics Reports Third Quarter 2022 Financial Results

INBRIJA® (levodopa inhalation powder) Q3 2022 U.S. net revenue of $7.8 million; 1% increase over Q3 2021 AMPYRA® (dalfampridine) Q3 2022 net revenue of $21.1 million; 5% increase over Q3 2021 $16.5M award